Brief: Bergenbio: Second Data Monitoring Committee Recommends Continuation Of BGBC020 Trial
08/02/2021 06:04
Feb 8 (Reuters) - Bergenbio ASA BGBIO.OL :
* BERGENBIO ASA: SECOND DATA MONITORING COMMITTEE RECOMMENDS
CONTINUATION OF BERGENBIO'S BGBC020 TRIAL ASSESSING BEMCENTINIB
IN COVID-19 PATIENTS
Source text for Eikon: ID:nWkrbhYMNV
Further company coverage: BGBIO.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587696600;))
Recent news on Oncoinvent ASA
See all newsBrief: Oncoinvent To Raise Up To NOK 140 Million In Private Placement
Brief: Oncoinvent H1 Operating Loss NOK 69 Mln
Brief: Oncoinvent Secures New Patent Expanding Protection For Radspherin
Brief: Oncoinvent's Shares To Be Consolidated In Ratio Of 100:1
Brief: Oncoinvent To Increase Share Capital In Connection With Settlement Of Underwriting Fee